# US 2025/0145601 A1 · Novel bicyclic compounds as rad51 inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145601 A1
- Document ID: US20250145601A1
- Status: Published application
- Kind: A1
- Application number: 18/837,659
- Filed: 2023-02-20
- Published: 2025-05-08
- Earliest claimed: 2022-02-22
- Assignees: Satya Therapeutics, Inc.
- Applicants: Satya Therapeutics, Inc.
- Inventors: Sanjita SASMAL; Venkatesham BOORGU; Shankar CHITHALURI
- Web page: https://patentgrep.com/patent/US20250145601A1

## CPC

- C07D 413/14: containing three or more hetero rings
- A61K 31/4365: the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/4725: containing further heterocyclic rings
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 35/00: Antineoplastic agents
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/14: containing three or more hetero rings
- C07D 405/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D 495/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to novel bicyclic compounds of formula (I) as inhibitors of RAD51 inhibitors, their pharmaceutically acceptable salts, solvates, polymorphs, tautomers, optical and geometric isomers thereof.

## Claims

### Claim 1

Novel bicyclic compounds of formula (I)
ring A is selected from 6-10 membered aryl, 5-10 membered heteroaryl, 6-10 membered cyclic ring system and 3-10 membered heterocyclyl;
ring B is selected from 6-10 membered aryl, 5-10 membered heteroaryl and 3-10 membered heterocyclyl;
ring C is selected from 6-10 membered aryl, 5-10 membered heteroaryl and 3-10 membered heterocyclyl;
wherein either of A or B or C is optionally substituted by one or more, identical or different substituents;
R1 and R2 is present or absent and when present is selected from the group consisting of hydrogen, halogen, alkyl, alkoxy, —C(O)alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl; wherein any of the group is optionally substituted by one or more, identical or different substituents;
R3 is selected from the group consisting of hydrogen, halogen, amino, nitro, alkyl, haloalkyl, alkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, heteroaryl;
R4 is selected from the group consisting of hydrogen, alkyl, —C(O)—R4a wherein any of the group is optionally substituted by one or more, identical or different substituents;
R4a is selected from the group consisting of hydrogen, alkyl, haloalkyl, cycloalkyl, heterocyclyl; wherein any of the group is optionally substituted by one or more, identical or different substituents;
R5 and R6 are same or different and each individually is selected from the group consisting of hydrogen, halogen, amino, nitro, alkyl, haloalkyl, cycloalkyl, alkoxy, acylamino, alkylamino, dialkylamino, heterocyclyl; wherein any of the group is optionally substituted by one or more, identical or different substituents;
R7 is selected from the group consisting of hydrogen, alkyl and
“n” is 0 to 2.

### Claim 2 (depends on 1)

The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt or a stereoisomer thereof, in which the ring A along with the attached ring is specifically represented by

### Claim 3 (depends on 1)

The novel bicyclic compounds of formula (I) according to claim 1 wherein the compound is formula (Ia)
or a pharmaceutically acceptable salt or a pharmaceutically acceptable regioisomer thereof;
wherein,
“x” is selected from O, S or N R′, wherein R′ is selected from hydrogen, alkyl;
“y” and “z” independently are selected from N, CR″, wherein R″ is selected from hydrogen, halogen, alkyl;
ring C is selected from 6-10 membered aryl, 5-10 membered heteroaryl and 3-10 membered heterocyclyl, optionally substituted by one or more, identical or different substituents;
R3 is selected from the group consisting of hydrogen, halogen, amino, nitro, alkyl, haloalkyl, alkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, heteroaryl;
R4 is selected from the group consisting of hydrogen, alkyl, —C(O)—R4a wherein any of the group is optionally substituted by one or more, identical or different substituents;
R4a is selected from the group consisting of hydrogen, alkyl, haloalkyl, cycloalkyl, heterocyclyl; wherein any of the group is optionally substituted by one or more, identical or different substituents;
R5 and R6 are same or different and each individually is selected from the group consisting of hydrogen, halogen, amino, nitro, alkyl, haloalkyl, cycloalkyl, alkoxy, acylamino, alkylamino, dialkylamino, heterocyclyl; wherein any of the group is optionally substituted by one or more, identical or different substituents;
R7 is selected from the group consisting of hydrogen, alkyl and
“n” is 0 to 2.

### Claim 4 (depends on 1)

The novel bicyclic compounds of formula (I) according to claim 1 wherein the compound is formula (Ib)
or a pharmaceutically acceptable salt or a pharmaceutically acceptable regioisomer thereof;
wherein,
ring C is selected from 6-10 membered aryl, 5-10 membered heteroaryl and 3-10 membered heterocyclyl, optionally substituted by one or more, identical or different substituents;
R1 and R2 is present or absent and when present is selected from the group consisting of hydrogen, halogen, alkyl, alkoxy, —C(O)alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl; wherein any of the group is optionally substituted by one or more, identical or different substituents;
R3 is selected from the group consisting of hydrogen, halogen, amino, nitro, alkyl, haloalkyl, alkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, heteroaryl;
R4 is selected from the group consisting of hydrogen, alkyl, —C(O)—R4a wherein any of the group is optionally substituted by one or more, identical or different substituents;
R4a is selected from the group consisting of hydrogen, alkyl, haloalkyl, cycloalkyl, heterocyclyl; wherein any of the group is optionally substituted by one or more, identical or different substituents;
R5 and R6 are same or different and each individually is selected from the group consisting of hydrogen, halogen, amino, nitro, alkyl, haloalkyl, cycloalkyl, alkoxy, acylamino, alkylamino, dialkylamino heterocyclyl; wherein any of the group is optionally substituted by one or more, identical or different substituents;
R7 is selected from the group consisting of hydrogen, alkyl and
“n” is 0 to 2.

### Claim 5 (depends on 1)

The novel bicyclic compounds of formula (I) according to claim 1 wherein the compound is formula (Ic)
or a pharmaceutically acceptable salt or a pharmaceutically acceptable regioisomer thereof;
wherein,
ring C is selected from 6-10 membered aryl, 5-10 membered heteroaryl and 3-10 membered heterocyclyl, optionally substituted by one or more, identical or different substituents;
“A”, “B”, “C”, and “D” independently are selected from O, S, NR′, C(R″)2, or any of the two A and B or C and D represent CR′ form a double bond, wherein R′ is absent or when present is selected from hydrogen, alkyl and R″ is hydrogen, halogen and alkyl;
R3 is selected from the group consisting of hydrogen, halogen, amino, nitro, alkyl, haloalkyl, alkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, heteroaryl;
R4 is selected from the group consisting of hydrogen, alkyl, —C(O)—R4a wherein any of the group is optionally substituted by one or more, identical or different substituents;
R4a is selected from the group consisting of hydrogen, alkyl, haloalkyl, cycloalkyl, heterocyclyl, wherein any of the group is optionally substituted by one or more, identical or different substituents;
R5 and R6 are same or different and each individually is selected from the group consisting of hydrogen, halogen, amino, nitro, alkyl, haloalkyl, cycloalkyl, alkoxy, acylamino, alkylamino, dialkylamino, heterocyclyl; wherein any of the group is optionally substituted by one or more, identical or different substituents;
R7 is selected from the group consisting of hydrogen, alkyl and
“n” is 0 to 2.

### Claim 6 (depends on 1)

The novel bicyclic compounds of formula (I) according to claim 1 wherein the compound is formula (Id)
or a pharmaceutically acceptable salt or a pharmaceutically acceptable regioisomer thereof;
wherein,
ring C is selected from 6-10 membered aryl, 5-10 membered heteroaryl and 3-10 membered heterocyclyl, optionally substituted by one or more, identical or different substituents;
R1 and R2 is present or absent and when present is selected from the group consisting of hydrogen, halogen, alkyl, alkoxy, —C(O)alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, wherein any of the group is optionally substituted by one or more, identical or different substituents;
R3 is selected from the group consisting of hydrogen, halogen, amino, nitro, alkyl, haloalkyl, hydroxyalkyl, cycloalkyl, heterocyclyl, heteroaryl;
R4 is selected from the group consisting of hydrogen, alkyl, —C(O)—R4a wherein any of the group is optionally substituted by one or more, identical or different substituents;
R4a is selected from the group consisting of hydrogen, alkyl, haloalkyl, cycloalkyl, heterocyclyl, wherein any of the group is optionally substituted by one or more, identical or different substituents;
R5 and R6 are same or different and each individually is selected from the group consisting of hydrogen, halogen, amino, nitro, alkyl, haloalkyl, cycloalkyl, alkoxy, acylamino, alkylamino, dialkylamino, heterocyclyl; wherein any of the group is optionally substituted by one or more, identical or different substituents;
R7 is selected from the group consisting of hydrogen, alkyl and
“n” is 0 to 2.

### Claim 7 (depends on 3)

The novel bicyclic compounds of formula (I) according to claim 3, wherein the ring C is specifically represented by

### Claim 8

A novel bicyclic compound selected from the group consisting of
1. 6-Chloro-3-(5-(4-methoxyphenyl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylquinolin-2(1H)-one
2. 6-Chloro-3-(1-(cyclopropanecarbonyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl)-4-methylquinolin-2(1H)-one
3. 6-chloro-3-(5-(4-methoxyphenyl)-1-(tetrahydro-2H-pyran-4-carbonyl)-4,5-dihydro-1H-pyrazol-3-yl)-4-methylquinolin-2(1H)-one
4. 6-chloro-3-(5-(4-methoxyphenyl)-1-(tetrahydrofuran-3-carbonyl)-4,5-dihydro-1H-pyrazol-3-yl)-4-methylquinolin-2(1H)-one
5. 6-Chloro-3-(5-(4-methoxyphenyl)-1-methyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylquinolin-2(1H)-one
6. 6-Chloro-4-methyl-3-(5-(1-methyl-1H-indol-6-yl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)quinolin-2(1H)-one
7. 6-chloro-3-(5-(6-methoxypyridin-3-yl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylquinolin-2(1H)-one
8. N-(4-(3-(6-chloro-4-methyl-2-oxo-1,2-dihydroquinolin-3-yl)-1-propionyl-4,5-dihydro-1H-pyrazol-5-yl)phenyl)propionamide
9. 3-(5-(4-Methoxyphenyl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methyl-1,5-naphthyridin-2(1H)-one
10. 4-Methyl-3-(5-(1-methyl-1H-indol-6-yl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)quinolin-2(1H)-one
11. 3-(5-(4-Methoxyphenyl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylquinolin-2(1H)-one
12. 4-Methyl-3-(5-(1-methyl-1H-indol-3-yl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)quinolin-2(1H)-one
13. 3-(5-(4-Methoxyphenyl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methyl-1,8-naphthyridin-2(1H)-one
14. 6-(5-(4-Methoxyphenyl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-5-methylpyrido-[2,3-d]pyrimidin-7(8H)-one
15. 6-bromo-3-(5-(4-methoxyphenyl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylquinolin-2(1H)-one
16. 6-chloro-3-(5-(4-methoxyphenyl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methyl-1,5-naphthyridin-2(1H)-one
17. 6-Chloro-3-(5-(4-methoxyphenyl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)quinolin-2(1H)-one
18. 6-chloro-3-(5-(4-methoxyphenyl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-1,4-dimethylquinolin-2(1H)-one
19. 4-(5-(4-methoxyphenyl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)isoquinolin-3(2H)-one
20. 5-(5-(4-Methoxyphenyl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylthieno-[2,3-b]pyridin-6(7H)-one
21. 5-(5-(6-methoxypyridin-3-yl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylthieno[2,3-b]pyridin-6(7H)-one
22. 5-(5-(4-methoxyphenyl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)thieno[2,3-b]pyridin-6(7H)-one
23. 6-chloro-4-cyclopropyl-3-(5-(4-methoxyphenyl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)quinolin-2(1H)-one
24. 6-chloro-4-methyl-3-(5-(1-methyl-1H-indol-3-yl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)quinolin-2(1H)-one
25. 5-(5-(5-methoxypyridin-2-yl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylthieno[2,3-b]pyridin-6(7H)-one
26. 4-methyl-5-(5-(6-oxo-1,6-dihydropyridin-3-yl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)thieno[2,3-b]pyridin-6(7H)-one
27. 5-(5-(4-fluorophenyl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylthieno[2,3-b]pyridin-6(7H)-one
28. 5-(5-(4-chlorophenyl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylthieno[2,3-b]pyridin-6(7H)-one
29. 5-(5-(5-methoxythiophen-2-yl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylthieno[2,3-b]pyridin-6(7H)-one
30. 5-(5-(2-methoxythiazol-5-yl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylthieno[2,3-b]pyridin-6(7H)-one
31. 5-(5-(5-bromothiophen-3-yl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylthieno[2,3-b]pyridin-6(7H)-one
32. 4-methyl-5-(5-phenyl-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)thieno[2,3-b]pyridin-6(7H)-one
33. 4-methyl-5-(1-propionyl-5-(thiophen-3-yl)-4,5-dihydro-1H-pyrazol-3-yl)thieno[2,3-b]pyridin-6(7H)-one
34. 5-(5-(4-bromothiophen-2-yl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylthieno[2,3-b]pyridin-6(7H)-one
35. 4-methyl-5-(1-propionyl-5-(pyridin-4-yl)-4,5-dihydro-1H-pyrazol-3-yl)thieno[2,3-b]pyridin-6(7H)-one
36. 4-methyl-5-(1-propionyl-5-(pyridin-3-yl)-4,5-dihydro-1H-pyrazol-3-yl)thieno[2,3-b]pyridin-6(7H)-one
37. 4-methyl-5-(1-propionyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)thieno[2,3-b]pyridin-6(7H)-one
38. 4-methyl-5-(5-(4-(4-methylpiperazin-1-yl)phenyl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)thieno[2,3-b]pyridin-6(7H)-one
39. 5-(5-(4-(dimethylamino)phenyl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylthieno[2,3-b]pyridin-6(7H)-one
40. 3-chloro-5-(5-(4-methoxyphenyl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylthieno[2,3-b]pyridin-6(7H)-one
41. 5-(5-(5-methylthiophen-2-yl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylthieno[2,3-b]pyridin-6(7H)-one
42. 4-methyl-5-(1-propionyl-5-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-pyrazol-3-yl)thieno[2,3-b]pyridin-6(7H)-one
43. 5-(5-(4-(difluoromethyl)phenyl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylthieno[2,3-b]pyridin-6(7H)-one
44. 5-(5-(4-ethylphenyl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylthieno[2,3-b]pyridin-6(7H)-one
45. 4-methyl-5-(5-(6-methylpyridin-3-yl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)thieno[2,3-b]pyridin-6(7H)-one
46. 4-methyl-5-(1-propionyl-5-(4-(pyrrolidin-1-yl)phenyl)-4,5-dihydro-1H-pyrazol-3-yl)thieno[2,3-b]pyridin-6(7H)-one
47. 5-(5-(4-cyclopropylphenyl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylthieno[2,3-b]pyridin-6(7H)-one
48. 4-methyl-5-(5-(2-methylthiazol-4-yl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)thieno[2,3-b]pyridin-6(7H)-one
49. 5-(5-(4-isopropylphenyl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylthieno[2,3-b]pyridin-6(7H)-one
50. 5-(5-(4,6-dimethylpyridin-3-yl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylthieno[2,3-b]pyridin-6(7H)-one
51. 4-methyl-5-(5-(2-methylpyrimidin-5-yl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)thieno[2,3-b]pyridin-6(7H)-one
52. 5-(5-(5-chloro-6-methylpyridin-3-yl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylthieno[2,3-b]pyridin-6(7H)-one
53. 5-(5-(4-methoxy-6-methylpyridin-3-yl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylthieno[2,3-b]pyridin-6(7H)-one
54. 5-(5-(5,6-dimethylpyridin-3-yl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylthieno[2,3-b]pyridin-6(7H)-one
55. 5-(5-(5-fluoro-6-methylpyridin-3-yl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylthieno[2,3-b]pyridin-6(7H)-one
56. 5-(5-(4-chloro-6-methylpyridin-3-yl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylthieno[2,3-b]pyridin-6(7H)-one
57. 4-methyl-5-(5-(2-methylthiazol-5-yl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)thieno[2,3-b]pyridin-6(7H)-one
58. 5-(5-cyclohexyl-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylthieno[2,3-b]pyridin-6(7H)-one
59. 6-chloro-4-methyl-3-(1-propionyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)quinolin-2(1H)-one
60. 4-methyl-3-(1-propionyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)quinolin-2(1H)-one
61. 6-chloro-4-methyl-3-(1-propionyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)-1,5-naphthyridin-2(1H)-one
62. 5-(1-acetyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)-4-methyl-7,7a-dihydrothieno[2,3-b]pyridin-6(7H)-one
63. 5-(1-isobutyryl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)-4-methyl-7,7a-dihydrothieno[2,3-b]pyridin-6(7H)-one
64. 4-methyl-5-(5-(p-tolyl)-1-(2,2,2-trifluoroacetyl)-4,5-dihydro-1H-pyrazol-3-yl)-7,7a-dihydrothieno[2,3-b]pyridin-6(7H)-one
65. 5-(5-(2-chloro-4-methylphenyl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylthieno[2,3-b]pyridin-6(7H)-one
66. 5-(5-(2-fluoro-4-methylphenyl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylthieno[2,3-b]pyridin-6(7H)-one
67. 6-chloro-4-methyl-3-(1-propionyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)-1,8-naphthyridin-2(1H)-one
68. 5-(5-(4-(fluoromethyl)phenyl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylthieno[2,3-b]pyridin-6(7H)-one
69. 4-methyl-3-(1-propionyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)-1,5-naphthyridin-2(1H)-one
70. 2,4-dimethyl-5-(1-propionyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)thieno[2,3-b]pyridin-6(7H)-one
71. 5-(5-benzyl-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylthieno[2,3-b]pyridin-6(7H)-one
72. 2-chloro-4-methyl-5-(1-propionyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)thieno[2,3-b]pyridin-6(7H)-one
73. 4-methyl-3-(1-propionyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)-1,8-naphthyridin-2(1H)-one
74. 4-methyl-3-(1-propionyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)-1,7-naphthyridin-2(1H)-one
75. 4,7-dimethyl-3-(1-propionyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)quinolin-2(1H)-one
76. 4,5-dimethyl-3-(1-propionyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)quinolin-2(1H)-one
77. 4-methyl-7-morpholino-3-(1-propionyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)quinolin-2(1H)-one
78. 4,8-dimethyl-3-(1-propionyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)-1,7-naphthyridin-2(1H)-one
79. 6-chloro-4-methyl-3-(1-propionyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)-1,7-naphthyridin-2(1H)-one′
80. 7-chloro-4-methyl-3-(1-propionyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)quinolin-2(1H)-one
81. 4,6-dimethyl-3-(1-propionyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)-1,7-naphthyridin-2(1H)-one
82. 4-methyl-7-(4-methylpiperazin-1-yl)-3-(1-propionyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)quinolin-2(1H)-one
83. 7-fluoro-4-methyl-3-(1-propionyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)quinolin-2(1H)-one
84. 4,7-dimethyl-3-(1-propionyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)-1,8-naphthyridin-2(1H)-one
85. 4-methyl-3-(1-propionyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)-1,6-naphthyridin-2(1H)-one
86. 4-methyl-7-morpholino-3-(1-propionyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)-1,8-naphthyridin-2(1H)-one
87. 7-(2-methoxyethoxy)-4-methyl-3-(1-propionyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)-1,8-naphthyridin-2(1H)-one
or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable regioisomer thereof.

### Claim 9

A novel bicyclic regioisomer compound selected from
(R)-5-(5-(4-methoxyphenyl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylthieno[2,3-b]pyridin-6(7H)-one
(S)-5-(5-(4-methoxyphenyl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylthieno[2,3-b]pyridin-6(7H)-one
(R)-5-(5-(4-chlorophenyl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylthieno[2,3-b]pyridin-6(7H)-one
(S)-5-(5-(4-chlorophenyl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylthieno[2,3-b]pyridin-6(7H)-one
(R)-4-methyl-5-(1-propionyl-5-(thiophen-3-yl)-4,5-dihydro-1H-pyrazol-3-yl)thieno[2,3-b]pyridin-6(7H)-one
(S)-4-methyl-5-(1-propionyl-5-(thiophen-3-yl)-4,5-dihydro-1H-pyrazol-3-yl)thieno[2,3-b]pyridin-6(7H)-one
(R)-4-methyl-5-(1-propionyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)thieno[2,3-b]pyridin-6(7H)-one
(S)-4-methyl-5-(1-propionyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)thieno[2,3-b]pyridin-6(7H)-one
(R)-4-methyl-5-(5-(6-methylpyridin-3-yl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)thieno[2,3-b]pyridin-6(7H)-one
(S)-4-methyl-5-(5-(6-methylpyridin-3-yl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)thieno[2,3-b]pyridin-6(7H)-one
(R)-4-methyl-3-(1-propionyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)quinolin-2(1H)-one
(S)-4-methyl-3-(1-propionyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)quinolin-2(1H)-one
(R)-5-(5-(2-fluoro-4-methylphenyl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylthieno[2,3-b]pyridin-6(7H)-one
(S)-5-(5-(2-fluoro-4-methylphenyl)-1-propionyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methylthieno[2,3-b]pyridin-6(7H)-one
(R)-4-methyl-3-(1-propionyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)-1,7-naphthyridin-2(1H)-one
(S)-4-methyl-3-(1-propionyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)-1,7-naphthyridin-2(1H)-one
(R)-4,8-dimethyl-3-(1-propionyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)-1,7-naphthyridin-2(1H)-one
(S)-4,8-dimethyl-3-(1-propionyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)-1,7-naphthyridin-2(1H)-one
(R)-7-chloro-4-methyl-3-(1-propionyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)quinolin-2(1H)-one
(S)-7-chloro-4-methyl-3-(1-propionyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)quinolin-2(1H)-one
(R)-4-methyl-7-(4-methylpiperazin-1-yl)-3-(1-propionyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)quinolin-2(1H)-one
(S)-4-methyl-7-(4-methylpiperazin-1-yl)-3-(1-propionyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)quinolin-2(1H)-one.

### Claim 10 (depends on 1)

The pharmaceutical composition, comprising at least one compound according to claim 1, or a pharmaceutically acceptable salt or a stereoisomer thereof and a pharmaceutically acceptable carrier or excipient.

### Claim 11 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt or a stereoisomer thereof, for use as a medicament.

### Claim 12 (depends on 1)

The method of inhibiting RAD51 protein comprising administering a therapeutically effective amount of a compound according to claim 1.

### Claim 13 (depends on 12)

The method as claimed in claim 12 for the treatment of cancer associated with RAD51 protein.

### Claim 14 (depends on 4)

The novel bicyclic compounds of formula (I) according to claim 4, wherein the ring C is specifically represented by

### Claim 15 (depends on 5)

The novel bicyclic compounds of formula (I) according to claim 5, wherein the ring C is specifically represented by

### Claim 16 (depends on 6)

The novel bicyclic compounds of formula (I) according to claim 6, wherein the ring C is specifically represented by

### Claim 17 (depends on 8)

The pharmaceutical composition, comprising at least one compound according to claim 8, or a pharmaceutically acceptable salt or a stereoisomer thereof and a pharmaceutically acceptable carrier or excipient.

### Claim 18 (depends on 8)

The compound according to claim 8, or a pharmaceutically acceptable salt or a stereoisomer thereof, for use as a medicament.

### Claim 19 (depends on 8)

The method of inhibiting RAD51 protein comprising administering a therapeutically effective amount of a compound according to claim 8.

### Claim 20 (depends on 19)

The method as claimed in claim 19 for the treatment of cancer associated with RAD51 protein.
